Harmony Biosciences (HRMY) Tops Q2 EPS by $1.05, provides guidance

Harmony Biosciences (NASDAQ: HRMY) reported Q2 EPS of $1.05. Revenue for the quarter came in at $172.8 million versus the consensus estimate of $173.24 million.

GUIDANCE:

Harmony Biosciences sees FY2024 revenue of $700-720 million, versus the consensus of $709.4 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Bessent: We Make A Market Buying Older Bonds
• Exclusive: J&J Snack Foods CEO sees a leaner business set up to return to growth
• B.Riley on Viking Therapeutic (VKTX): 'we continue to see an attractive setup'